Cerci, K., & Patir, P. (2023). Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation. Global Journal of Medical and Clinical Case Reports, 10(1), 001–002. https://doi.org/10.17352/2455-5282.000167